abrdn plc purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 128,670 shares of the biopharmaceutical company's stock, valued at approximately $6,152,000. abrdn plc owned approximately 0.10% of Halozyme Therapeutics at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the stock. Verdence Capital Advisors LLC grew its position in shares of Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company's stock worth $757,000 after buying an additional 252 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 350 shares in the last quarter. Juncture Wealth Strategies LLC lifted its stake in Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock worth $690,000 after purchasing an additional 415 shares during the last quarter. Diversify Advisory Services LLC lifted its stake in Halozyme Therapeutics by 8.5% during the third quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company's stock worth $305,000 after purchasing an additional 418 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC lifted its stake in Halozyme Therapeutics by 7.7% during the third quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company's stock worth $407,000 after purchasing an additional 507 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.
Insider Activity at Halozyme Therapeutics
In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.40% of the company's stock.
Halozyme Therapeutics Stock Performance
HALO stock traded up $0.78 during mid-day trading on Wednesday, reaching $58.11. The company had a trading volume of 888,165 shares, compared to its average volume of 1,286,692. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a market capitalization of $7.39 billion, a P/E ratio of 19.24, a P/E/G ratio of 0.44 and a beta of 1.25. Halozyme Therapeutics, Inc. has a one year low of $34.36 and a one year high of $65.53. The stock's 50-day simple moving average is $52.09 and its two-hundred day simple moving average is $54.45.
Analyst Ratings Changes
Several equities analysts recently issued reports on HALO shares. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $60.89.
View Our Latest Stock Analysis on Halozyme Therapeutics
About Halozyme Therapeutics
(
Free Report)
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Further Reading
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
